IRONWOOD PHARMACEUTICALS, INC. Capital Expenditures Incurred but Not yet Paid
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Capital Expenditures Incurred but Not yet Paid of $1.28 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-18.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2022-02-18
- IRONWOOD PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2019 was $1.28M.
| Period end | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|
| 2019-12-31 | $1.28M 10-K · filed 2022-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |